Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus

BMC Immunology - Tập 4 - Trang 1-9 - 2003
Rosetta Pedotti1,2, Maija Sanna3, Mindy Tsai4, Jason DeVoss1, Lawrence Steinman1, Hugh McDevitt3, Stephen J Galli4
1Department of Neurology and Neurological Science, Stanford University School of Medicine, Stanford, USA
2Neuroimmunology Unit, Instituto Neurologico C. Besta, Milan, Italy
3Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, USA
4Department of Pathology, Stanford University School of Medicine, Stanford, USA

Tóm tắt

Insulin dependent (i.e., "type 1") diabetes mellitus (T1DM) is considered to be a T cell mediated disease in which TH1 and Tc autoreactive cells attack the pancreatic islets. Among the beta-cell antigens implicated in T1DM, glutamic acid decarboxylase (GAD) 65 appears to play a key role in the development of T1DM in humans as well as in non-obese diabetic (NOD) mice, the experimental model for this disease. It has been shown that shifting the immune response to this antigen from TH1 towards TH2, via the administration of GAD65 peptides to young NOD mice, can suppress the progression to overt T1DM. Accordingly, various protocols of "peptide immunotherapy" of T1DM are under investigation. However, in mice with experimental autoimmune encephalomyelitis (EAE), another autoimmune TH1 mediated disease that mimics human multiple sclerosis, anaphylactic shock can occur when the mice are challenged with certain myelin self peptides that initially were administered with adjuvant to induce the disease. Here we show that NOD mice, that spontaneously develop T1DM, can develop fatal anaphylactic reactions upon challenge with preparations of immunodominant GAD65 self peptides after immunization with these peptides to modify the development of T1DM. These findings document severe anaphylaxis to self peptide preparations used in an attempt to devise immunotherapy for a spontaneous autoimmune disease. Taken together with the findings in EAE, these results suggest that peptide therapies designed to induce a TH1 to TH2 shift carry a risk for the development of anaphylactic reactivity to the therapeutic peptides.

Tài liệu tham khảo

Tisch R, McDevitt H: Insulin-dependent diabetes mellitus. Cell. 1996, 85: 291-297. Bao M, Yang Y, Jun HS, Yoon JW: Molecular mechanisms for gender differences in susceptibility to T cell- mediated autoimmune diabetes in nonobese diabetic mice. J Immunol. 2002, 168: 5369-5375. Acha-Orbea H, McDevitt HO: The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. Proc Natl Acad Sci U S A. 1987, 84: 2435-2439. Singer SM, Tisch R, Yang XD, Sytwu HK, Liblau R, McDevitt HO: Prevention of diabetes in NOD mice by a mutated I-Ab transgene. Diabetes. 1998, 47: 1570-1577. Chao CC, Sytwu HK, Chen EL, Toma J, McDevitt HO: The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. Proc Natl Acad Sci U S A. 1999, 96: 9299-9304. 10.1073/pnas.96.16.9299. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, DeCamilli P, Camilli PD: Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990, 347: 151-156. 10.1038/347151a0. Hagopian WA, Karlsen AE, Gottsater A, Landin-Olsson M, Grubin CE, Sundkvist G, Petersen JS, Boel E, Dyrberg T, Lernmark A: Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J Clin Invest. 1993, 91: 368-374. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO: Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature. 1993, 366: 72-75. 10.1038/366072a0. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV: Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature. 1993, 366: 69-72. 10.1038/366069a0. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO: Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes. 1998, 47: 894-899. Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, Martin R, Utz U, Karin N, Mitchell D: Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein [published erratum appears in Nature 1998 Apr 9;392(6676):630]. Nature. 1996, 379: 343-346. 10.1038/379343a0. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK: An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity. 1995, 3: 397-405. Ruiz PJ, Garren H, Ruiz IU, Hirschberg DL, Nguyen LV, Karpuj MV, Cooper MT, Mitchell DJ, Fathman CG, Steinman L: Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. J Immunol. 1999, 162: 3336-3341. Pedotti R, Mitchell D, Wedemeyer J, Karpuj M, Chabas D, Hattab EM, Tsai M, Galli SJ, Steinman L: An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol. 2001, 2: 216-222. 10.1038/85266. Liu E, Moriyama H, Abiru N, Miao D, Yu L, Taylor RM, Finkelman FD, Eisenbarth GS: Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest. 2002, 110: 1021-1027. 10.1172/JCI200215488. Liu FT, Bohn JW, Ferry EL, Yamamoto H, Molinaro CA, Sherman LA, Klinman NP, Katz DH: Monoclonal dinitrophenyl-specific murine IgE antibody: preparation, isolation, and characterization. J Immunol. 1980, 124: 2728-2737. Miyajima I, Dombrowicz D, Martin TR, Ravetch JV, Kinet JP, Galli SJ: Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J Clin Invest. 1997, 99: 901-914. Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, Geha RS: Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest. 1998, 101: 1614-1622. Hutchings P, Cooke A: Protection from insulin dependent diabetes mellitus afforded by insulin antigens in incomplete Freund's adjuvant depends on route of administration. J Autoimmun. 1998, 11: 127-130. 10.1006/jaut.1997.0184. Ramiya VK, Shang XZ, Pharis PG, Wasserfall CH, Stabler TV, Muir AB, Schatz DA, Maclaren NK: Antigen based therapies to prevent diabetes in NOD mice. J Autoimmun. 1996, 9: 349-356. 10.1006/jaut.1996.0047. Williams CM, Galli SJ: The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol. 2000, 105: 847-859. 10.1067/mai.2000.106485. So T, Ito H, Hirata M, Ueda T, Imoto T: Contribution of conformational stability of hen lysozyme to induction of type 2 T-helper immune responses. Immunology. 2001, 104: 259-268. 10.1046/j.1365-2567.2001.01314.x. Vaysburd M, Lock C, McDevitt H: Prevention of insulin-dependent diabetes mellitus in nonobese diabetic mice by immunogenic but not by tolerated peptides. J Exp Med. 1995, 182: 897-902. Derbinski J, Schulte A, Kyewski B, Klein L: Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol. 2001, 2: 1032-1039. 10.1038/ni723. Kishimoto H, Sprent J: A defect in central tolerance in NOD mice. Nat Immunol. 2001, 2: 1025-1031. 10.1038/ni726. Lesage S, Goodnow CC: Organ-specific autoimmune disease: a deficiency of tolerogenic stimulation. J Exp Med. 2001, 194: F31-NaN. 10.1084/jem.194.5.F31. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV: Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature. 1996, 379: 346-349. 10.1038/379346a0. Ujike A, Ishikawa Y, Ono M, Yuasa T, Yoshino T, Fukumoto M, Ravetch JV, Takai T: Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low- affinity Fc receptors for IgG. J Exp Med. 1999, 189: 1573-1579. 10.1084/jem.189.10.1573. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L: Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med. 2000, 6: 1176-1182. 10.1038/80525.